HealthcareServices

Viral Vector-Based Gene Therapy Market Forecast 2026–2035: Data Trends and Industry Insights

March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the viral vector-based gene therapy market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Viral Vector-Based Gene Therapy Market in 2026, and what figure is it projected to hit by 2030?

The viral vector-based gene therapy market has experienced swift expansion recently. This market is projected to expand from $6.77 billion in 2025 to $7.93 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.2%. Historically, this expansion has been driven by progress in molecular biology research, a deeper comprehension of genetic disorders, initial positive outcomes from viral vector treatments, the broadening scope of orphan drug initiatives, and the accessibility of various viral vector platforms.

The viral vector-based gene therapy market size is projected to experience substantial expansion in the coming years, reaching $14.81 billion by 2030, driven by a compound annual growth rate (CAGR) of 16.9%. This anticipated growth during the forecast period is attributable to several factors, including the increasing number of approved gene therapy products, a rise in investment dedicated to rare disease treatments, the broadening scope of precision medicine initiatives, the expanding embrace of personalized healthcare, and ongoing advancements in vector engineering technologies. Key trends anticipated within this period encompass the increasing acceptance of targeted gene therapies, the progressive evolution of individualized treatment methods, a wider range of clinical trials addressing rare diseases, a heightened concentration on achieving long-lasting therapeutic effectiveness, and a stronger focus on the safety and performance of vectors.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30431&type=smp

Which Drivers Are Affecting Market Participation In The Viral Vector-Based Gene Therapy Market?

The increasing frequency of genetic diseases is expected to propel the expansion of the viral vector-based gene therapy market moving forward. Genetic diseases are health conditions caused by changes or mutations in DNA, which can be inherited or develop spontaneously, impacting an individual’s health, development, or overall bodily functions. The rising incidence of these diseases is linked to increased awareness and advancements in diagnostic technologies, which allow for earlier and more accurate detection of conditions that might have previously gone undiagnosed. Viral vector-based gene therapy enhances the management of genetic diseases by providing targeted delivery of therapeutic genes, making it an ideal approach for treating inherited disorders. This therapy helps reduce disease progression by enabling precise and lasting correction of genetic defects, thereby improving patient outcomes and their quality of life. For instance, in April 2025, according to the International Diabetes Federation (IDF), a Belgium-based non-profit organization, approximately 589 million people were living with diabetes in 2024, and this number is projected to rise to 853 million by 2050. Therefore, the growing prevalence of genetic diseases is a significant driver for the viral vector-based gene therapy market.

What Segment Classifications Make Up The Viral Vector-Based Gene Therapy Market?

The viral vector-based gene therapy market covered in this report is segmented –

1) By Vector Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors

2) By Delivery Method: Intravenous Injection, Intrathecal Injection, Intramuscular Injection, Subcutaneous Injection, Topical

3) By Application: Oncology, Genetic Disorders, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Other Applications

4) By End-User: Hospitals, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Adenoviral Vectors: Human Adenovirus Serotype Five, Human Adenovirus Serotype Two, Canine Adenovirus

2) By Adeno-Associated Viral Vectors: Adeno-Associated Virus Serotype One, Adeno-Associated Virus Serotype Two, Adeno-Associated Virus Serotype Five, Adeno-Associated Virus Serotype Eight, Other Adeno-Associated Viruses

3) By Lentiviral Vectors: Human Immunodeficiency Virus One, Human Immunodeficiency Virus Two

4) By Retroviral Vectors: Gammaretrovirus, Alpharetrovirus, Spumaretrovirus, Other Retroviruses

What Trends Are Driving The Growth Trajectory Of The Viral Vector-Based Gene Therapy Market?

Leading companies in the viral vector-based gene therapy market are prioritizing the creation of advanced solutions, such as integrated manufacturing platforms, to improve efficiency, increase dependability, and minimize the expense and duration of therapy production. These integrated manufacturing platforms are defined as extensive systems designed to optimize the full gene therapy production journey, spanning from vector conceptualization to the finished therapeutic, by employing uniform, highly productive methodologies. A notable example is Forge Biologics Holdings LLC, a US-based biotechnology company, which introduced the FUEL AAV Manufacturing Platform in October 2024. This platform is a proprietary, suspension-based manufacturing system engineered to deliver high productivity and scalability. Comprising a fully integrated plasmid system and refined methodologies, it facilitates the dependable and uniform generation of adeno-associated viral (AAV) vectors for gene therapies, consequently expediting development schedules from research stages to clinical trials.

Which Leading Companies Dominate The Viral Vector-Based Gene Therapy Market Share?

Major companies operating in the viral vector-based gene therapy market are F. Hoffmann-La Roche AG, Novartis AG, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Inc., Rocket Pharmaceuticals Inc., PTC Therapeutics Inc., 4D Molecular Therapeutics Inc., Editas Medicine Inc., Regenxbio Inc., Oxford Biomedica plc, MeiraGTx Holdings plc, Voyager Therapeutics Inc., Solid Biosciences Inc., Sangamo Therapeutics Inc., Adverum Biotechnologies Inc., Passage Bio Inc., Dyno Therapeutics Inc., uniQure N.V., Bluebird Bio Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/global-viral-vector-based-gene-therapy-market-report

Which Region Is Anticipated To See The Fastest Growth In The Viral Vector-Based Gene Therapy Market?

North America was the largest region in the viral vector-based gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector-based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Viral Vector-Based Gene Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30431&type=smp

Browse Through More Reports Similar to the Global Viral Vector-Based Gene Therapy Market 2026, By The Business Research Company

Oral Expectorant Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795